Pathophysiology of multiple sclerosis and the place of teriflunomide

Acta Neurologica Scandinavica

Volumn 124, Issue 2, 2011, Pages 75-84

  Gold, R ^a   Wolinsky, J S ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Disease modifying therapies; Immunology; Immunomodulator; Multiple sclerosis; Relapsing remitting; Teriflunomide

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; BETA1A INTERFERON; CREATINE KINASE; GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN; MIDAZOLAM; PLACEBO; TERIFLUNOMIDE; WARFARIN;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; BLOOD BRAIN BARRIER; CELLULAR IMMUNITY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; GENETIC MANIPULATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPATHOGENESIS; LIMB PAIN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEURALGIA; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PARESTHESIA; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CROTONIC ACIDS; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; TOLUIDINES;

EID: 79953016820     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01444.x     Document Type: Review

References (48)

1. Bruck W, Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 2005;18:221-4.
2. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ 2000;321:490-4.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
4. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin 1996;14:291-308.
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
6. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46.
7. Montalban X. Primary progressive multiple sclerosis. Curr Opin Neurol 2005;18:261-6.
8. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
9. Inglese M. Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol 2006;27:954-7.
10. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-55.
11. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-94.
12. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
13. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76.
14. Dangond F. Multiple sclerosis. In: Emedicine Neurology. (accessed 24 August 2009).
15. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009;132:1146-60.
16. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-10.
17. Oksenberg JR, Hauser SL. Genetics of multiple sclerosis. Neurol Clin 2005;23:61-75.
18. Kantarci OH. Genetics and natural history of multiple sclerosis. Semin Neurol 2008;28:7-16.
19. Barcellos LF, Oksenberg JR, Begovich AB et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-6.
20. Haines JL, Bradford Y, Garcia ME et al. Multiple susceptibility loci for multiple sclerosis. Hum Mol Genet 2002;11:2251-6.
21. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008;131:3118-31.
22. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
23. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21.
24. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-71.
25. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43-72.
26. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-9.
27. Tzartos JS, Friese MA, Craner MJ et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55.
28. Flugel A, Odoardi F, Nosov M, Kawakami N. Autoaggressive effector T cells in the course of experimental autoimmune encephalomyelitis visualized in the light of two-photon microscopy. J Neuroimmunol 2007;191:86-97.
29. Korn T, Mitsdoerffer M, Kuchroo VK. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple Sclerosis. Results Probl Cell Differ 2010;51:43-74.
30. Costello K. An overview of multiple sclerosis: diagnosis and management strategies. In: Topics in Advance Practice Nursing [online]. (accessed 24 August 2009).
31. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007;21:483-502.
32. Ruggieri M, Avolio C, Livrea P, Trojano M. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev 2007;13:178-91.
33. Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs 2008;13:465-77.
34. Bruneau JM, Yea CM, Spinella-Jaegle S et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998;336:299-303.
35. Cherwinski HM, Cohn RG, Cheung P et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.
36. Ruckemann K, Fairbanks LD, Carrey EA et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
37. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61:635-42.
38. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
39. Merrill JE, Hanak S, Pu SF et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009;256:89-103.
40. Mcmonagle-Strucko K, Hanak S, Pu SF et al. Teriflunomide reduces neurological behaviour and pathology in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Presented at 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 11, 2009; Dusseldorf.
41. Petty M, Lee L, Ying X et al. Teriflunomide treatment reduces infiltration of macrophages, T cells and B cells, and increases survival of oligodendrocytes in the spinal cord of the Dark Agouti rat model of Experimental Allergic Encephalomyelitis. Presented at the Annual Meeting of the American Academy of Neurology (AAN); April 15, 2010; Toronto, Canada.
42. Merrill JE. In vitro and in vivo pharmacological models to assess demyelination and remyelination. Neuropsychopharmacology 2009;34:55-73.
43. Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of MS. Presented at the Annual Meeting of the American Academy of Neurology (AAN); April 15, 2010; Toronto.
44. Sanofi-Aventis. Data on file.
45. O'connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
46. O'connor PW, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Traboulsee A. Oral teriflunomide is effective and well tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension study. Presented at 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 28, 2006; Madrid.
47. Freedman MS, Wolinsky JS, Byrnes WJ et al. Oral teriflunomide or placebo to added to interferon beta for 6months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 11, 2009; Dusseldorf.
48. Freedman MS, Wolinsky JS, Frangin GA et al. Oral teriflunomide or placebo added to glatiramer acetate for 6months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at the Annual Meeting of the American Academy of Neurology (AAN); April 14, 2010; Toronto.